BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.

Mirum Pharmaceuticals Inc. – Material Contracts

NASDAQ: MIRM    
Share price (6/2/26): $92.17    
Market cap (6/2/26): $5.621 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from SCHEDULE 13D/A ~1 page Transactions Relating to the Common Stock of the Issuer During the Past Sixty (60) Days
12/34/56
EX-10.2
from 8-K 23 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 22 pages Subscription Agreement
12/34/56
EX-10.2
from 8-K 23 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 23 pages Subscription Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy as Amended April 4, 2024, Effective as of April 4, 2024
12/34/56
EX-10.5
from 10-Q 4 pages Re: Employment Terms Dear Joanne, It Is My Pleasure to Offer You Employment With Mirum Pharmaceuticals, Inc. (The “Company”) on the Terms Set Forth in This Offer Letter (This “Offer Letter”). We Are Building the Premier Rare Liver Disease Company and Are Excited to Have You as Part of the Team. the Terms of the Offer Are as Follows: Title: Chief Medical Officer Start Date: Tuesday, January 16, 2024
12/34/56
EX-10.2
from 10-Q 9 pages Mirum Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice
12/34/56
EX-10.1
from 10-Q 3 pages Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy as Amended [ ], 2024, Effective as of [ ], 2024
12/34/56
EX-10.16A
from 10-K 5 pages Third Amendment
12/34/56
EX-10.19
from 10-K 3 pages Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.17
from 10-K 50 pages Office Lease Metro Center 989 East Hillsdale Boulevard Foster City, California Between Hudson Metro Center, LLC, a Delaware Limited Liability Company as Landlord, and Mirum Pharmaceuticals, Inc., a Delaware Corporation as Tenant Office Lease
12/34/56
EX-10.4
from 10-K 23 pages Mirum Pharmaceuticals, Inc. 2020 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: March 18, 2020 Amended by the Compensation Committee of the Board of Directors: December 16, 2020 Amended by the Compensation Committee of the Board of Directors: November 18, 2021 Amended by the Compensation Committee of the Board of Directors: August 24, 2023
12/34/56
EX-10.3
from 10-Q 43 pages Mirum Pharmaceuticals, Inc. Shares of Common Stock ($0.0001 Par Value Per Share) Sales Agreement
12/34/56
EX-10.1
from 8-K 3 pages August 8, 2023 Eric Bjerkholt […***…] Re: Employment Terms Dear Eric, It Is My Pleasure to Offer You Employment With Mirum Pharmaceuticals, Inc. (The “Company”) on the Terms Set Forth in This Offer Letter (This “Offer Letter”). We Are Building the Premier Rare Liver Disease Company and Are Excited to Have You as Part of the Team. the Terms of the Offer Are as Follows: Title: Chief Financial Officer Start Date: Monday, September 11, 2023
12/34/56
EX-10.1
from 8-K 24 pages Mirum Pharmaceuticals, Inc. Severance Benefit Plan Approved by the Board of Directors: November 30, 2018 Amended and Restated: August 24, 2023
12/34/56
EX-10.1
from 10-Q 19 pages Subscription Agreement
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 18 pages Subscription Agreement
12/34/56
EX-10
from 10-K 23 pages Mirum Pharmaceuticals, Inc. 2020 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: March 18, 2020 Amended by the Compensation Committee of the Board of Directors: December 16, 2020 Amended by the Compensation Committee of the Board of Directors: November 18, 2021
12/34/56